Table 1.
Baseline Characteristics of Participants According to Quartiles of SUA/SCr Ratio
| Characteristics | Total | Quartiles of SUA/SCr ratio | P value | |||
|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | |||
| No. of participants | 96 378 | 24 094 | 24 095 | 24 095 | 24 094 | |
| SUA/SCr ratio | 3.17 (2.54–3.92) | 2.14 (1.83–2.36) | 2.87 (2.71–3.02) | 3.51 (3.33–3.71) | 4.55 (4.20–5.15) | <0.0001 |
| Age, y | 51.48±12.57 | 50.62±12.23 | 51.57±12.53 | 51.64±12.63 | 52.08±12.83 | <0.0001 |
| Men, n (%) | 76 662 (79.54) | 18 424 (76.47) | 18 809 (78.06) | 19 526 (81.04) | 19 903 (82.61) | <0.0001 |
| High school or above, n (%) | 6528 (7.01) | 993 (4.24) | 1536 (6.61) | 1898 (8.18) | 2101 (9.05) | <0.0001 |
| Income ≥800 RMB/mo, n (%) | 13 209 (14.20) | 2382 (10.19) | 3065 (13.20) | 3615 (15.59) | 4147 (17.88) | <0.0001 |
| Current smoker, n (%) | 32 089 (34.21) | 6280 (26.82) | 7766 (33.23) | 8742 (37.21) | 9301 (39.52) | <0.0001 |
| Current alcohol, n (%) | 35 142 (37.45) | 6287 (26.83) | 8241 (35.25) | 9720 (41.37) | 10 894 (46.29) | <0.0001 |
| Active physical activity, n (%) | 13 994 (14.52) | 2895 (12.02) | 3377 (14.02) | 3709 (15.39) | 4013 (16.66) | <0.0001 |
| Hypertension, n (%) | 41 633 (43.20) | 11 199 (46.48) | 9969 (41.37) | 9738 (40.42) | 10 727 (44.52) | <0.0001 |
| Diabetes, n (%) | 8709 (9.04) | 2751 (11.42) | 2156 (8.95) | 1892 (7.85) | 1910 (7.93) | <0.0001 |
| Dyslipidemia, n (%) | 33 137 (34.38) | 7285 (30.24) | 7566 (31.40) | 8339 (34.61) | 9947 (41.28) | <0.0001 |
| Proteinuria ≥1+, n (%) | 3414 (3.72) | 1196 (5.09) | 741 (3.20) | 667 (2.91) | 810 (3.63) | <0.0001 |
| Antihypertensive agents, n (%) | 9436 (9.79) | 1631 (6.77) | 2038 (8.46) | 2444 (10.14) | 3323 (13.79) | <0.0001 |
| Diuretics, n (%) | 962 (1.03) | 123 (0.53) | 152 (0.65) | 228 (0.98) | 459 (1.98) | <0.0001 |
| ACEI/ARB treatment, n (%) | 647 (0.70) | 95 (0.41) | 144 (0.62) | 162 (0.70) | 246 (1.06) | <0.0001 |
| Hypoglycemic agents, n (%) | 2061 (2.14) | 594 (2.46) | 519 (2.15) | 480 (1.99) | 468 (1.94) | 0.0002 |
| Lipid‐lowering agents, n (%) | 709 (0.74) | 116 (0.48) | 161 (0.67) | 176 (0.73) | 256 (1.06) | <0.0001 |
| Body mass index, kg/m2 | 25.02±3.49 | 24.72±3.34 | 24.80±3.48 | 25.07±3.52 | 25.49±3.57 | <0.0001 |
| Systolic blood pressure, mm Hg | 130.64±20.88 | 131.09±20.63 | 130.14±21.15 | 129.79±20.63 | 131.52±21.08 | <0.0001 |
| Diastolic blood pressure, mm Hg | 83.38±11.76 | 83.55±11.66 | 83.05±11.85 | 82.85±11.66 | 84.08±11.82 | <0.0001 |
| Total cholesterol, mg/dL | 4.95±1.15 | 4.78±1.27 | 4.92±1.09 | 5.00±1.05 | 5.08±1.14 | <0.0001 |
| Triglyceride, mg/dL | 1.67±1.37 | 1.53±1.20 | 1.63±1.28 | 1.64±1.38 | 1.89±1.57 | <0.0001 |
| HDL‐C, mg/dL | 1.55±0.4 | 1.59±0.39 | 1.54±0.40 | 1.53±0.41 | 1.54±0.41 | <0.0001 |
| LDL‐C, mg/dL | 2.34±0.91 | 2.30±0.91 | 2.29±0.90 | 2.33±0.93 | 2.46±0.89 | <0.0001 |
| Fasting blood glucose, mmol/L | 5.47±1.67 | 5.62±2.04 | 5.44±1.65 | 5.40±1.49 | 5.42±1.41 | <0.0001 |
| hs‐CRP, mg/L | 2.39±6.48 | 2.13±6.93 | 2.32±6.24 | 2.38±5.72 | 2.72±6.91 | <0.0001 |
ACEI indicates angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; HDL‐C, high density lipoprotein cholesterol; hs‐CRP, high sensitivity C‐reactive protein; LDL‐C, low density lipoprotein cholesterol; SCr, serum creatinine; and SUA, serum uric acid.